FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2777766975> ?p ?o ?g. }

• W2777766975 endingPage "109" @default.
• W2777766975 startingPage "99" @default.
• W2777766975 abstract "Although overall survival rate for patients with thyroid cancer (TC) is high, there is an alarming 10-year recurrence rate of up to 30% conferring a ~50% survival among these high-risk patients. The BRAFV600E mutation is estimated to be present in over 50% of papillary thyroid cancer (PTC) cases besides being associated with carcinogenesis and poor prognosis. We assessed the status of NF-κB, Ki-67, cyclin D1 and BRAFV600E in TC tissues and TC cell lines using immunohistochemistry and Western blot analysis. Concurrently, we evaluated the outcomes of combined targeting of the proteasome pathway in addition to selective BRAF inhibitors in cases of PTC. In this study, BRAFV600E-bearing TC cells were treated with BRAFV600E inhibitor, Vemurafenib alone or in combination with the proteasome inhibitor, Bortezomib. The combination of both drugs showed synergistic effects as evidenced by cell growth inhibition (P < 0.05), increased G2-phase cell cycle arrest and induced apoptosis (P < 0.05). In our TC xenograft model, the combination of Vemurafenib and Bortezomib significantly reduced tumor size (P < 0.05) and expression of the markers of cell growth and proliferation, Ki-67 and cyclin D1 (P < 0.001), when compared to monotherapy. Further analysis demonstrated that treatment with Bortezomib sensitized TC cells to Vemurafenib via mitochondrial dysregulation and apoptosis of TC cells, as evidenced by the increase in the expression of p53, Noxa protein, the loss of mitochondrial membrane potential, cytochrome c release and Poly (ADP-ribose) polymerase cleavage. Our results demonstrate a strong clinical potential for the combination of the Bortezomib and the BRAF inhibitor Vemurafenib as an efficient therapeutic approach for the treatment of TC." @default.
• W2777766975 created "2018-01-05" @default.
• W2777766975 creator A5014064754 @default.
• W2777766975 creator A5017345022 @default.
• W2777766975 creator A5022836469 @default.
• W2777766975 creator A5046333510 @default.
• W2777766975 creator A5048170482 @default.
• W2777766975 creator A5069504677 @default.
• W2777766975 creator A5071277883 @default.
• W2777766975 creator A5079091531 @default.
• W2777766975 creator A5080754826 @default.
• W2777766975 creator A5081251185 @default.
• W2777766975 creator A5091747497 @default.
• W2777766975 date "2018-01-01" @default.
• W2777766975 modified "2023-09-27" @default.
• W2777766975 title "Bortezomib sensitizes thyroid cancer to BRAF inhibitor in vitro and in vivo" @default.
• W2777766975 cites W1514408827 @default.
• W2777766975 cites W1965011810 @default.
• W2777766975 cites W1969918370 @default.
• W2777766975 cites W1972603204 @default.
• W2777766975 cites W1982355744 @default.
• W2777766975 cites W1982393730 @default.
• W2777766975 cites W1987204096 @default.
• W2777766975 cites W1989579274 @default.
• W2777766975 cites W2009925064 @default.
• W2777766975 cites W2010552629 @default.
• W2777766975 cites W2011826559 @default.
• W2777766975 cites W2012127421 @default.
• W2777766975 cites W2020058375 @default.
• W2777766975 cites W2021469872 @default.
• W2777766975 cites W2033480787 @default.
• W2777766975 cites W2040642592 @default.
• W2777766975 cites W2050921960 @default.
• W2777766975 cites W2051323297 @default.
• W2777766975 cites W2077040802 @default.
• W2777766975 cites W2078766933 @default.
• W2777766975 cites W2082715516 @default.
• W2777766975 cites W2091550153 @default.
• W2777766975 cites W2096120060 @default.
• W2777766975 cites W2102161942 @default.
• W2777766975 cites W2111458745 @default.
• W2777766975 cites W2118307179 @default.
• W2777766975 cites W2120683183 @default.
• W2777766975 cites W2124662474 @default.
• W2777766975 cites W2125095362 @default.
• W2777766975 cites W2125637620 @default.
• W2777766975 cites W2126670362 @default.
• W2777766975 cites W2128308297 @default.
• W2777766975 cites W2129899548 @default.
• W2777766975 cites W2138126697 @default.
• W2777766975 cites W2138310647 @default.
• W2777766975 cites W2151027772 @default.
• W2777766975 cites W2154748904 @default.
• W2777766975 cites W2155242492 @default.
• W2777766975 cites W2159902630 @default.
• W2777766975 cites W2168076926 @default.
• W2777766975 cites W2169390530 @default.
• W2777766975 cites W2323016503 @default.
• W2777766975 cites W2330588857 @default.
• W2777766975 cites W2488131695 @default.
• W2777766975 cites W2558749613 @default.
• W2777766975 cites W2559746652 @default.
• W2777766975 cites W2588601193 @default.
• W2777766975 cites W2591333392 @default.
• W2777766975 doi "https://doi.org/10.1530/erc-17-0182" @default.
• W2777766975 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29269566" @default.
• W2777766975 hasPublicationYear "2018" @default.
• W2777766975 type Work @default.
• W2777766975 sameAs 2777766975 @default.
• W2777766975 citedByCount "20" @default.
• W2777766975 countsByYear W27777669752019 @default.
• W2777766975 countsByYear W27777669752020 @default.
• W2777766975 countsByYear W27777669752021 @default.
• W2777766975 countsByYear W27777669752022 @default.
• W2777766975 countsByYear W27777669752023 @default.
• W2777766975 crossrefType "journal-article" @default.
• W2777766975 hasAuthorship W2777766975A5014064754 @default.
• W2777766975 hasAuthorship W2777766975A5017345022 @default.
• W2777766975 hasAuthorship W2777766975A5022836469 @default.
• W2777766975 hasAuthorship W2777766975A5046333510 @default.
• W2777766975 hasAuthorship W2777766975A5048170482 @default.
• W2777766975 hasAuthorship W2777766975A5069504677 @default.
• W2777766975 hasAuthorship W2777766975A5071277883 @default.
• W2777766975 hasAuthorship W2777766975A5079091531 @default.
• W2777766975 hasAuthorship W2777766975A5080754826 @default.
• W2777766975 hasAuthorship W2777766975A5081251185 @default.
• W2777766975 hasAuthorship W2777766975A5091747497 @default.
• W2777766975 hasBestOaLocation W27777669751 @default.
• W2777766975 hasConcept C121608353 @default.
• W2777766975 hasConcept C126322002 @default.
• W2777766975 hasConcept C185592680 @default.
• W2777766975 hasConcept C190283241 @default.
• W2777766975 hasConcept C199835354 @default.
• W2777766975 hasConcept C2776131300 @default.
• W2777766975 hasConcept C2776364478 @default.
• W2777766975 hasConcept C2777478702 @default.
• W2777766975 hasConcept C2777658100 @default.
• W2777766975 hasConcept C2778367456 @default.

• next